Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608274 | 0.88 | SIGMAR1 (0.76) | SIGMAR1KCNH2HTR2BCYP1A2CYP3A4 | |
| SCHEMBL1135542 | 0.87 | SIGMAR1 (0.55) | SIGMAR1KCNH2HTR2B | |
| SCHEMBL8274194 | 0.87 | SIGMAR1 (0.70) | SIGMAR1KCNH2HTR2BCYP1A2CYP3A4 | |
| SCHEMBL467324 | 0.83 | SIGMAR1 (1.00) | SIGMAR1KCNH2HTR2B | |
| SCHEMBL467349 | 0.82 | SIGMAR1 (1.00) | SIGMAR1KCNH2HTR2B | |
| SCHEMBL4523328 | 0.81 | SIGMAR1 (0.71) | SIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1894793 | 0.81 | SIGMAR1 (0.98) | SIGMAR1KCNH2HTR2B | |
| SCHEMBL467090 | 0.81 | SIGMAR1 (1.00) | SIGMAR1KCNH2HTR2B | |
| Hydrochloric Acid SCHEMBL29557756 | 0.81 | SIGMAR1 (0.98) | SIGMAR1KCNH2HTR2B | |
| SCHEMBL1135428 | 0.81 | SIGMAR1 (0.62) | SIGMAR1KCNH2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646435-B1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2646435-B1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-8729073-B2 | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-05-20 | — | — | US | disclosed |
| US-8729073-B2 | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-05-20 | — | — | US | disclosed |
| US-8729073-B2 | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-05-20 | — | — | US | disclosed |
| US-20130303540-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20130303540-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20130303540-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| EP-2646435-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012072781-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012072781-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-07 | — | — | WO | disclosed |
| EP-2460804-A1 | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460804-A1 | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303540-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLE DERIVATIVES AND THEIR USE IN POTENTIATING THE EFFECT OF OPIOID ANALGESICS | OPRK1, OPRD1, OPRM1 | SIGMAR1 7/4885KCNH2 702/4885HTR2B 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.